##fileformat=VCFv4.1
##fileDate=20201028
##source=Ingenuity VCS 6.0.20200609
##LabTestID=Hereditary Cancer Demo
##reference=NCBIb37
##INFO=<ID=GENE_REGION,Number=.,Type=String,Description="Gene region containing variant,Header=Gene Region">
##INFO=<ID=GENE_SYMBOL,Number=.,Type=String,Description="Gene containing variant,Header=Gene Symbol">
##INFO=<ID=TRANSCRIPT_ID,Number=.,Type=String,Description="Transcript containing variant,Header=Transcript ID">
##INFO=<ID=HGVS_TRANSCRIPT,Number=.,Type=String,Description="HGVS transcript variant,Header=Transcript Variant">
##INFO=<ID=HGVS_PROTEIN,Number=.,Type=String,Description="HGVS protein variant,Header=Protein Variant">
##INFO=<ID=TRANSLATION_IMPACT,Number=.,Type=String,Description="Translation impact,Header=Translation Impact">
##INFO=<ID=SIFT_FUNCTION,Number=.,Type=String,Description="SIFT functional prediction,Source=SIFT,Version=2016-02-23,Header=SIFT Function Prediction">
##INFO=<ID=POLYPHEN_FUNCTION,Number=.,Type=String,Description="PolyPhen-2 functional prediction,Source=Polyphen-2,Version=v2.2.2,Header=PolyPhen-2 Function Prediction">
##INFO=<ID=BLOSUM50,Number=.,Type=Float,Description="BLOSUM50 biochemical conservation score">
##INFO=<ID=PHYLOP,Number=.,Type=Float,Description="PhyloP vertebrate conservation p-value,Source=PhyloP,Version=2009-11,Header=Conservation phyloP p-value">
##INFO=<ID=ING_FINDINGS,Number=.,Type=Float,Description="Ingenuity variant findings,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=ING_CLASSIFICATION,Number=.,Type=String,Description="Ingenuity computed clinical classification,Header=Classification">
##INFO=<ID=ING_PHENOTYPE,Number=.,Type=String,Description="Phenotype for variant assessment">
##INFO=<ID=AFC_AF,Number=.,Type=Float,Description="AFC allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC Frequency">
##INFO=<ID=AFC_AF_EAS,Number=.,Type=Float,Description="AFC East Asian allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC East Asian Frequency">
##INFO=<ID=AFC_AF_SAS,Number=.,Type=Float,Description="AFC South Asian allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC South Asian Frequency">
##INFO=<ID=AFC_AF_AFR,Number=.,Type=Float,Description="AFC African American allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC African Frequency">
##INFO=<ID=AFC_AF_EUR,Number=.,Type=Float,Description="AFC European allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC European Frequency">
##INFO=<ID=AFC_AF_LAT,Number=.,Type=Float,Description="AFC Latino allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC Latino Frequency">
##INFO=<ID=AFC_AF_AJ,Number=.,Type=Float,Description="AFC Ashkenazi Jewish allele frequency (percent),Source=QIAGEN,Version=2019-09-25,Header=AFC Ashkenazi Jewish Frequency">
##INFO=<ID=DBSNP,Number=.,Type=String,Description="dbSNP identifiers,Source=dbSNP,Version=151,Header=dbSNP ID">
##INFO=<ID=1000G_AF,Number=.,Type=Float,Description="1000 Genomes project allele frequency (percent),Source=1000 Genomes,Version=phase3v5b,Header=1000 Genomes Frequency">
##INFO=<ID=ESP_AF,Number=.,Type=Float,Description="Exome Server Project allele frequency (percent),Source=EVS,Version=ESP6500SI-V2,Header=NHLBI ESP Frequency">
##INFO=<ID=ESP_AF_AA,Number=.,Type=Float,Description="Exome Server Project African American allele frequency (percent),Source=EVS,Version=ESP6500SI-V2,Header=NHLBI ESP African Frequency">
##INFO=<ID=ESP_AF_EA,Number=.,Type=Float,Description="Exome Server Project European American allele frequency (percent),Source=EVS,Version=ESP6500SI-V2,Header=NHLBI ESP European Frequency">
##INFO=<ID=ING_DRUGGED_GENE,Number=.,Type=String,Description="Does an approved drug target this gene?,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=ING_PGX_DRUGS,Number=.,Type=String,Description="Approved drug(s) with a pharmacogenetic effect,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=ESP_PUBLIC_HOMOZYGOTES,Number=.,Type=Float,Description="Exome Server Project homozygotes,Source=EVS,Version=ESP6500SI-V2">
##INFO=<ID=ING_MIN_PROTEIN_LENGTH,Number=.,Type=Float,Description="Minimal functional protein length">
##INFO=<ID=ING_COMPLEX_VARIANT,Number=.,Type=String,Description="Do any variant findings indicate variant contributes to complex genetics,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=CLINVAR_OBSERVATIONS,Number=.,Type=Float,Description="Number of individuals reported with this variant in ClinVar,Source=ClinVar,Version=2019-11-06">
##INFO=<ID=CLINVAR,Number=.,Type=String,Description="Reference ClinVar accession,Source=ClinVar,Version=09/10/2015">
##INFO=<ID=ING_AFFECTED,Number=.,Type=Float,Description="Number of affected individuals with variant reported in the literature,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=ING_AFFECTED_HOM,Number=.,Type=Float,Description="Number of affected homozygous individuals for variant reported in the literature,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=ING_UNAFFECTED,Number=.,Type=Float,Description="Number of unaffected individuals with variant reported in the literature,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=PUBMED,Number=.,Type=String,Description="PubMed identifiers for articles about this variant">
##INFO=<ID=ING_FUNCTIONAL_VALIDATION,Number=.,Type=String,Description="Type of functional validation observed">
##INFO=<ID=ING_DISCORDANT_FAMILIES,Number=.,Type=Float,Description="Number of families with affected individuals who lack claimed causal variant,Source=Ingenuity Knowledge Base,Version=X-release">
##INFO=<ID=CLI_ASSESSMENT,Number=.,Type=String,Description="Laboratory assessment of variant">
##INFO=<ID=CLI_REPORTABLE,Number=.,Type=String,Description="Whether and where variant should be included in report">
##INFO=<ID=END,Number=1,Type=Integer,Description="End position of the variant described in this record">
##INFO=<ID=SVLEN,Number=.,Type=Integer,Description="Difference in length between REF and ALT alleles">
##INFO=<ID=SVTYPE,Number=1,Type=String,Description="Type of structural variant">
##INFO=<ID=CADD,Number=.,Type=Float,Description="CADD PHRED Score,Header=CADD PHRED Score. For SNV variants having a CADD score below 10, two values will be used to represent the min, max">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
##FORMAT=<ID=CQ,Number=1,Type=Float,Description="Call Quality">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read Depth">
##FORMAT=<ID=ING_AF,Number=1,Type=Float,Description="Ingenuity Computed Allele Fraction,Header=Allele Fraction (percent)">
##FORMAT=<ID=AD,Number=.,Type=Integer,Description="Allelic Depth, unfiltered count of all reads">
##FORMAT=<ID=CN,Number=.,Type=Integer,Description="Copy Number">
##FORMAT=<ID=GQ,Number=1,Type=Float,Description="Genotype Quality">
##FORMAT=<ID=ING_CH,Number=1,Type=String,Description="Ingenuity Inferred Compound Heterozygous">
##FORMAT=<ID=ING_IA,Number=1,Type=String,Description="Ingenuity Inferred Activity">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	EVS_TEST
chr2	47601029	.	G	C	200	PASS	DBSNP=146480420;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Possibly_Damaging;AFC_AF=0.254;AFC_AF_EAS=0.000;AFC_AF_SAS=0.033;AFC_AF_AFR=0.115;AFC_AF_EUR=0.428;AFC_AF_LAT=0.207;AFC_AF_AJ=0.165;1000G_AF=0.100;ESP_AF=0.431;ESP_AF_AA=0.136;ESP_AF_EA=0.581;ING_FINDINGS=15;ING_CLASSIFICATION=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=18.710;ESP_PUBLIC_HOMOZYGOTES=0.43057048;ING_AFFECTED=7;PUBMED=redacted;TRANSCRIPT_ID=ENST00000263735.8;HGVS_TRANSCRIPT=c.267G>C;HGVS_PROTEIN=p.Q89H;GENE_REGION=Exonic;GENE_SYMBOL=EPCAM;TRANSLATION_IMPACT=missense;BLOSUM50=1;ING_MIN_PROTEIN_LENGTH=314	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:200:2652:.:.,.:.:.:.:normal
chr2	47601029	.	G	C	200	PASS	DBSNP=146480420;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Possibly_Damaging;AFC_AF=0.254;AFC_AF_EAS=0.000;AFC_AF_SAS=0.033;AFC_AF_AFR=0.115;AFC_AF_EUR=0.428;AFC_AF_LAT=0.207;AFC_AF_AJ=0.165;1000G_AF=0.100;ESP_AF=0.431;ESP_AF_AA=0.136;ESP_AF_EA=0.581;ING_FINDINGS=15;ING_CLASSIFICATION=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=18.710;ESP_PUBLIC_HOMOZYGOTES=0.43057048;ING_AFFECTED=7;PUBMED=redacted;TRANSCRIPT_ID=NM_002354.2;HGVS_TRANSCRIPT=c.267G>C;HGVS_PROTEIN=p.Q89H;GENE_REGION=Exonic;GENE_SYMBOL=EPCAM;TRANSLATION_IMPACT=missense;BLOSUM50=1;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000115770.2,RCV000123185.8,RCV000589651.1,RCV000664266.1,RCV000524486.1;ING_MIN_PROTEIN_LENGTH=314	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:200:2652:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322011.2;HGVS_TRANSCRIPT=c.28G>A;HGVS_PROTEIN=p.V10I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=551	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322009.2;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=738	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322015.2;HGVS_TRANSCRIPT=c.652G>A;HGVS_PROTEIN=p.V218I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=759	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=ENST00000382321.5;HGVS_TRANSCRIPT=c.803+5326G>A;GENE_REGION=Intronic;GENE_SYMBOL=PMS2;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=461	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322004.2;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=727	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NR_136154.1;HGVS_TRANSCRIPT=n.1048G>A;GENE_REGION=ncRNA;GENE_SYMBOL=PMS2;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=-1	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322010.2;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=675	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322008.2;HGVS_TRANSCRIPT=c.643G>A;HGVS_PROTEIN=p.V215I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=756	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_000535.7;HGVS_TRANSCRIPT=c.961G>A;HGVS_PROTEIN=p.V321I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=862	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322003.2;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=727	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322014.2;HGVS_TRANSCRIPT=c.961G>A;HGVS_PROTEIN=p.V321I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=873	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=ENST00000642292.1;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=727	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322013.2;HGVS_TRANSCRIPT=c.388G>A;HGVS_PROTEIN=p.V130I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=671	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=ENST00000265849.12;HGVS_TRANSCRIPT=c.961G>A;HGVS_PROTEIN=p.V321I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=862	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322012.2;HGVS_TRANSCRIPT=c.28G>A;HGVS_PROTEIN=p.V10I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=551	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322006.2;HGVS_TRANSCRIPT=c.961G>A;HGVS_PROTEIN=p.V321I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=810	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=ENST00000642456.1;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=727	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=ENST00000644110.1;HGVS_TRANSCRIPT=c.643G>A;HGVS_PROTEIN=p.V215I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=756	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322007.1;HGVS_TRANSCRIPT=c.643G>A;HGVS_PROTEIN=p.V215I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=756	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr7	6031631	.	C	T	100	PASS	DBSNP=377043696;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=3.776E-3;AFC_AF=0.004;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.008;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ESP_AF=0.008;ESP_AF_AA=0.000;ESP_AF_EA=0.012;ING_FINDINGS=6;ING_CLASSIFICATION=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=21.000;ESP_PUBLIC_HOMOZYGOTES=0.007688759;ING_AFFECTED=5;PUBMED=redacted;TRANSCRIPT_ID=NM_001322005.2;HGVS_TRANSCRIPT=c.556G>A;HGVS_PROTEIN=p.V186I;GENE_REGION=Exonic;GENE_SYMBOL=PMS2;TRANSLATION_IMPACT=missense;BLOSUM50=4;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000130331.5,RCV000222996.2,RCV000206806.7;ING_MIN_PROTEIN_LENGTH=727	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr11	108139302	.	C	A	100	PASS	DBSNP=3218708;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.000;AFC_AF_EAS=0.004;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.000;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=2;CLI_ASSESSMENT=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;TRANSCRIPT_ID=NM_001351834.2;HGVS_TRANSCRIPT=c.2804C>A;HGVS_PROTEIN=p.T935K;GENE_REGION=Exonic;GENE_SYMBOL=ATM;TRANSLATION_IMPACT=missense;BLOSUM50=-1;ING_MIN_PROTEIN_LENGTH=3056	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr11	108139302	.	C	A	100	PASS	DBSNP=3218708;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.000;AFC_AF_EAS=0.004;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.000;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=2;CLI_ASSESSMENT=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;TRANSCRIPT_ID=NM_000051.3;HGVS_TRANSCRIPT=c.2804C>A;HGVS_PROTEIN=p.T935K;GENE_REGION=Exonic;GENE_SYMBOL=ATM;TRANSLATION_IMPACT=missense;BLOSUM50=-1;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000691001.1,RCV000777372.1;ING_MIN_PROTEIN_LENGTH=3056	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr11	108139302	.	C	A	100	PASS	DBSNP=3218708;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.000;AFC_AF_EAS=0.004;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.000;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=2;CLI_ASSESSMENT=Uncertain_Significance;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;TRANSCRIPT_ID=ENST00000452508.6;HGVS_TRANSCRIPT=c.2804C>A;HGVS_PROTEIN=p.T935K;GENE_REGION=Exonic;GENE_SYMBOL=ATM;TRANSLATION_IMPACT=missense;BLOSUM50=-1;ING_MIN_PROTEIN_LENGTH=3056	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr13	32972533	.	C	T	100	PASS	DBSNP=80359247;AFC_AF=0.001;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.000;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=7;ING_CLASSIFICATION=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=42.000;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_000059.3;HGVS_TRANSCRIPT=c.9883C>T;HGVS_PROTEIN=p.Q3295*;GENE_REGION=Exonic;GENE_SYMBOL=BRCA2;TRANSLATION_IMPACT=stop_gain;CLINVAR_OBSERVATIONS=1;CLINVAR=RCV000496879.1,RCV000112819.3,RCV000238720.2;ING_MIN_PROTEIN_LENGTH=3418	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr13	32972533	.	C	T	100	PASS	DBSNP=80359247;AFC_AF=0.001;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.000;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=7;ING_CLASSIFICATION=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CADD=42.000;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000544455.5;HGVS_TRANSCRIPT=c.9883C>T;HGVS_PROTEIN=p.Q3295*;GENE_REGION=Exonic;GENE_SYMBOL=BRCA2;TRANSLATION_IMPACT=stop_gain;CLINVAR_OBSERVATIONS=1;CLINVAR=RCV000496879.1,RCV000112819.3,RCV000238720.2;ING_MIN_PROTEIN_LENGTH=3418	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=NM_004360.5;HGVS_TRANSCRIPT=c.2077G>A;HGVS_PROTEIN=p.G693S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=882	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=NM_001317185.2;HGVS_TRANSCRIPT=c.529G>A;HGVS_PROTEIN=p.G177S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=366	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=ENST00000422392.6;HGVS_TRANSCRIPT=c.1894G>A;HGVS_PROTEIN=p.G632S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=821	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=NM_001317186.2;HGVS_TRANSCRIPT=c.112G>A;HGVS_PROTEIN=p.G38S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=227	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=ENST00000261769.10;HGVS_TRANSCRIPT=c.2077G>A;HGVS_PROTEIN=p.G693S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=882	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr16	68857442	.	G	A	100	PASS	DBSNP=386833398;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;AFC_AF=0.003;AFC_AF_EAS=0.000;AFC_AF_SAS=0.003;AFC_AF_AFR=0.004;AFC_AF_EUR=0.006;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=4;CLI_ASSESSMENT=Likely_Benign;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Not_Reportable;CADD=0.000,10.000;ING_AFFECTED=3;PUBMED=redacted;TRANSCRIPT_ID=NM_001317184.2;HGVS_TRANSCRIPT=c.1894G>A;HGVS_PROTEIN=p.G632S;GENE_REGION=Exonic;GENE_SYMBOL=CDH1;TRANSLATION_IMPACT=missense;BLOSUM50=0;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000129247.4,RCV000034707.1;ING_MIN_PROTEIN_LENGTH=821	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:normal
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000610623.4;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=187	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126115.1;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=261	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000359597.8;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=343	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126113.2;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=346	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276699.2;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=187	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000610538.4;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=307	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276760.2;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126114.2;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=341	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000620739.4;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_000546.5;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;CLINVAR_OBSERVATIONS=0;CLINVAR=RCV000179771.1;ING_MIN_PROTEIN_LENGTH=393	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276696.2;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=302	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126117.1;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=214	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276697.2;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=234	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126116.1;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=209	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276698.2;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=182	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000420246.6;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=341	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000413465.6;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=285	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000610292.4;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000269305.8;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=393	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000619186.4;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=234	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000622645.4;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=302	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000617185.4;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=341	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126118.1;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000504937.5;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=261	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276695.2;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=307	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000504290.5;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=214	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000619485.4;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000510385.5;HGVS_TRANSCRIPT=c.308_313delACTACA;HGVS_PROTEIN=p.N103_Y104del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=209	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000455263.6;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=346	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000445888.6;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=393	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=ENST00000618944.4;HGVS_TRANSCRIPT=c.227_232delACTACA;HGVS_PROTEIN=p.N76_Y77del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=182	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001126112.2;HGVS_TRANSCRIPT=c.704_709delACTACA;HGVS_PROTEIN=p.N235_Y236del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=393	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	7577577	.	TTGTAGT	T	100	PASS	PHYLOP=4.831E-5;ING_FINDINGS=4;ING_CLASSIFICATION=Likely_Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;ING_AFFECTED=4;PUBMED=redacted;TRANSCRIPT_ID=NM_001276761.2;HGVS_TRANSCRIPT=c.587_592delACTACA;HGVS_PROTEIN=p.N196_Y197del;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=in-frame;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NM_007294.3;HGVS_TRANSCRIPT=c.5363G>T;HGVS_PROTEIN=p.G1788V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;CLINVAR_OBSERVATIONS=17;CLINVAR=RCV000048961.8,RCV000235698.3,RCV000162885.2,RCV000031241.6;ING_MIN_PROTEIN_LENGTH=1863	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000591849.5;HGVS_TRANSCRIPT=c.62G>T;HGVS_PROTEIN=p.G21V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=96	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NM_007298.3;HGVS_TRANSCRIPT=c.2051G>T;HGVS_PROTEIN=p.G684V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=759	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NM_007300.4;HGVS_TRANSCRIPT=c.5426G>T;HGVS_PROTEIN=p.G1809V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=1884	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000586385.5;HGVS_TRANSCRIPT=c.293G>T;HGVS_PROTEIN=p.G98V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=173	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NM_007297.4;HGVS_TRANSCRIPT=c.5222G>T;HGVS_PROTEIN=p.G1741V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=1816	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000468300.5;HGVS_TRANSCRIPT=c.2021-1461G>T;GENE_REGION=Intronic;GENE_SYMBOL=BRCA1;ING_MIN_PROTEIN_LENGTH=699	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000357654.8;HGVS_TRANSCRIPT=c.5363G>T;HGVS_PROTEIN=p.G1788V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=1863	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000591534.5;HGVS_TRANSCRIPT=c.836G>T;HGVS_PROTEIN=p.G279V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=354	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NM_007299.4;HGVS_TRANSCRIPT=c.2021-1461G>T;GENE_REGION=Intronic;GENE_SYMBOL=BRCA1;ING_MIN_PROTEIN_LENGTH=699	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=ENST00000471181.7;HGVS_TRANSCRIPT=c.5426G>T;HGVS_PROTEIN=p.G1809V;GENE_REGION=Exonic;GENE_SYMBOL=BRCA1;TRANSLATION_IMPACT=missense;BLOSUM50=-4;ING_MIN_PROTEIN_LENGTH=1884	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss
chr17	41201181	.	C	A	100	PASS	DBSNP=80357069;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION=Benign;PHYLOP=7.278E-4;AFC_AF=0.000;AFC_AF_EAS=0.000;AFC_AF_SAS=0.000;AFC_AF_AFR=0.000;AFC_AF_EUR=0.001;AFC_AF_LAT=0.000;AFC_AF_AJ=0.000;ING_FINDINGS=28;CLI_ASSESSMENT=Pathogenic;ING_PHENOTYPE=Hereditary_cancer-predisposing_syndrome;CLI_REPORTABLE=Reportable;CADD=26.300;ING_PGX_DRUGS=rucaparib;ING_AFFECTED=45;PUBMED=redacted;ING_FUNCTIONAL_VALIDATION=some,loss;TRANSCRIPT_ID=NR_027676.2;HGVS_TRANSCRIPT=n.5540G>T;GENE_REGION=ncRNA;GENE_SYMBOL=BRCA1;ING_MIN_PROTEIN_LENGTH=-1	GT:CQ:DP:ING_AF:AD:CN:GQ:ING_CH:ING_IA	0/1:100:5:.:.,.:.:.:.:loss